Anaphylaxis: Clinical concepts and research priorities

EMA - Emergency Medicine Australasia

Volumn 18, Issue 2, 2006, Pages 155-169

  Brown, Simon G A ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c NONE   (Australia)

Author keywords

Aetiology; Anaphylaxis; Classification; Diagnosis; Drug therapy; Physiopathology

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAGON; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; HYPERTENSIVE AGENT; IMMUNOGLOBULIN E ANTIBODY; INOTROPIC AGENT; METARAMINOL; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; PREDNISONE; PROMETHAZINE; SALBUTAMOL; SEROTONIN; SODIUM CHLORIDE; STEROID; VASOPRESSIN; VENOM;

ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AORTA BALLOON; ASTHMA; ATOPY; BODY POSTURE; BOLUS INJECTION; BRADYCARDIA; BRONCHOSPASM; CLINICAL FEATURE; CLINICAL RESEARCH; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; ECHOCARDIOGRAPHY; EFFECTOR CELL; EMERGENCY CARE; EXTRAVASATION; FOLLOW UP; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOTHERAPY; LIQUID; MEDIATOR; MYOCARDIAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OBSERVATIONAL STUDY; PALLOR; PANIC; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; RESUSCITATION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SMOOTH MUSCLE CONTRACTION; STRIDOR; STROKE; SUPINE POSITION; TACHYCARDIA; TONGUE SWELLING; TREATMENT FAILURE; TREMOR; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT OBSTRUCTION; URTICARIA; VASODILATATION; VISUAL IMPAIRMENT;

ADRENERGIC AGONISTS; ANAPHYLAXIS; ANIMALS; EPINEPHRINE; HISTAMINE H1 ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; RESEARCH; RISK ASSESSMENT;

EID: 33645716251     PISSN: 17426731     EISSN: 17426723     Source Type: Journal    
DOI: 10.1111/j.1742-6723.2006.00831.x     Document Type: Review

References (81)

1. Brown AFT. The emergency department epidemiology of acute allergic events: can we ever compare apples with apples? Emerg. Med. 2003 15 315 17.
2. Fisher MM More DG. The epidemiology and clinical features of anaphylactic reactions in anaesthesia. Anaesth. Intensive Care 1981 9 226 34.
3. Fisher MM. Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anaesth. Intensive Care 1986 14 17 21.
4. Brown AFT McKinnon D Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J. Allergy Clin. Immunol. 2001 108 861 6.
5. Brown SGA. Clinical features and severity grading of anaphylaxis. J. Allergy Clin. Immunol. 2004 114 371 6.
6. Brown SGA Blackman KE Stenlake V Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and Volume resuscitation. Emerg. Med. J. 2004 21 149 54.
7. Braganza SC Acworth JP McKinnon DRL Peake JE Brown AFT. Paediatric emergency department anaphylaxis: different patterns from adults. Arch. Dis. Child. 2006 91 159 63.
8. Pumphrey RS Roberts IS. Postmortem findings after fatal anaphylactic reactions. J. Clin. Pathol. 2000 53 273 6.
9. Johansson SG Bieber T Dahl R et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 2004 113 832 6.
10. Sampson HA Munoz-Furlong A Campbell R et al. Second symposium on the definition and management of anaphylaxis: summary report. J. Allergy Clin. Immunol. 2006 117 391 7.
11. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr. Opin. Allergy Clin. Immunol. 2004 4 285 90.
12. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin. Exp. Allergy 2000 30 1144 50.
13. Sampson HA Mendelson L Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N. Engl. J. Med. 1992 327 380 4.
14. Brown SGA Franks RW Baldo BA Heddle RJ. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. J. Allergy Clin. Immunol. 2003 111 187 92.
15. Settipane GA Klein DE Boyd GK. Relationship of atopy and anaphylactic sensitization: a bee sting allergy model. Clin. Allergy 1978 8 259 65.
16. Brown SGA. Preventing anaphylaxis to venom of the jack jumper ant. Doctor of Philosophy Thesis. Flinders University of South Australia 2003. Available from URL: http://voyager.flinders.edu.au/local/adt/public/adt-SFU20050707. 103356/ [Accessed 12 December 2005].
17. van der Linden PW Hack CE Struyvenberg A van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J. Allergy Clin. Immunol. 1994 94 2 Pt 1 151 9.
18. van Halteren HK van der Linden PW Burgers SA Bartelink AK. Hymenoptera sting challenge of 348 patients: relation to subsequent field stings. J. Allergy Clin. Immunol. 1996 97 1058 63.
19. Mueller HL. Diagnosis and treatment of insect sensitivity. J. Asthma Res. 1966 3 331 3.
20. Lockey RF Turkeltaub PC Olive ES Hubbard JM Baird-Warren IA Bukantz SC. The Hymenoptera venom study. III: safety of venom immunotherapy. J. Allergy Clin. Immunol. 1990 86 775 80.
21. Genovese A Stellato C Marsella CV Adt M Marone G. Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Int. Arch. Allergy Immunol. 1996 110 13 22.
22. Kemp SF Lockey RF. Anaphylaxis: a review of causes and mechanisms. J. Allergy Clin. Immunol. 2002 110 341 8.
23. Lasser EC. The radiocontrast molecule in anaphylaxis: a surprising antigen. Novartis Found. Symp. 2004 257 211 24 discussion: 224-5, 276-85.
24. Morcos SK. Acute serious and fatal reactions to contrast media: our current understanding [Review article]. Br. J. Radiol. 2005 78 686 93.
25. Ring J Brockow K Behrendt H. History and classification of anaphylaxis. Novartis Found. Symp. 2004 257 6 16 discussion: 16-24, 45-50, 276-85.
26. Douglas R Weiner J Abrahamson M O'Hehir R. Prevalence of severe ant venom allergy in southeastern Australia. J. Allergy Clin. Immunol. 1998 101 129 31.
27. Solley GO. Stinging and biting insect allergy: an Australian experience. Ann. Allergy Asthma Immunol. 2004 93 532 7.
28. Brown AFT. Anaphylactic shock - mechanisms and treatment. Emerg. Med. 1994 6 319 30.
29. Williams CM Galli SJ. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. 2000 105 847 59.
30. Smith PL Kagey-Sobotka A Bleecker ER et al. Physiologic manifestations of human anaphylaxis. J. Clin. Invest. 1980 66 1072 80.
31. Schummer W Schummer C Wippermann J Fuchs J. Anaphylactic shock: is vasopressin the drug of choice? Anesthesiology 2004 101 1025 7.
32. Heytman M Rainbird A. Use of alpha-agonists for management of anaphylaxis occurring under anaesthesia: case studies and review. Anaesthesia 2004 59 1210 15.
33. McBrien ME Webb ST Breslin DS. Anaphylaxis and anaesthesia. Br. J. Anaesth. 2005 94 547 8 author reply: 548.
34. Kill C Wranze E Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int. Arch. Allergy Immunol. 2004 134 260 1.
35. Mink SN Simons FE Simons KJ Becker AB Duke K. Constant infusion of epinephrine, but not bolus treatment, improves haemodynamic recovery in anaphylactic shock in dogs. Clin. Exp. Allergy 2004 34 1776 83.
36. Brown SGA Wiese MD Blackman KE Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003 361 1001 6.
37. Schadt JC Ludbrook J. Hemodynamic and neurohumoral responses to acute hypovolemia in conscious mammals. Am. J. Physiol. 1991 260 2 Pt 2 H305 18.
38. Patella V Marino I Lamparter B Arbustini E Adt M Marone G. Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. J. Immunol. 1995 154 2855 65.
39. Cooper DJ. Cardiac dysfunction during anaphylaxis in patients. Appl. Cardiopulm. Pathophysiol. 1993 5 9 18.
40. Hanashiro PK Weil MH. Anaphylactic shock in man. Report of two cases with detailed hemodynamic and metabolic studies. Arch. Intern. Med. 1967 119 129 40.
41. Raper RF Fisher MM. Profound reversible myocardial depression after anaphylaxis. Lancet 1988 1 386 8.
42. Wittstein IS Thiemann DR Lima JA et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N. Engl. J. Med. 2005 352 539 48.
43. Meszaros I. Transient cerebral ischemic attack caused by Hymenoptera stings: the brain as an anaphylactic shock organ. Eur. Neurol. 1986 25 248 52.
44. Starr JC Brasher GW. Wasp sting anaphylaxis with cerebral infarction. Ann. Allergy 1977 39 431 3.
45. Koutsojannis CM Kounis NG. Lepirudin anaphylaxis and Kounis syndrome. Circulation 2004 109 e315 author reply: e315.
46. Nikolaidis LA Kounis NG Gradman AH. Allergic angina and allergic myocardial infarction: a new twist on an old syndrome. Can. J. Cardiol. 2002 18 508 11.
47. Emergency medical treatment of anaphylactic reactions. Project Team of The Resuscitation Council (UK). Resuscitation 1999 41 93 9.
48. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: Part 10.6: Anaphylaxis. Circulation 2005 112 24 Suppl. IV 143-5.
49. Lieberman P Kemp SF Oppenheimer J et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J. Allergy Clin. Immunol. 2005 115 3 Pt 2 S483 523.
50. Simons FE Gu X Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J. Allergy Clin. Immunol. 2001 108 871 3.
51. Simons FE Roberts JR Gu X Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J. Allergy Clin. Immunol. 1998 101 1 Pt 1 33 7.
52. Bautista E Simons FE Simons KJ et al. Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock. Int. Arch. Allergy Immunol. 2002 128 151 64.
53. Pumphrey RS. Fatal posture in anaphylactic shock. J. Allergy Clin. Immunol. 2003 112 451 2.
54. van der Linden PW Struyvenberg A Kraaijenhagen RJ Hack CE van der Zwan JK. Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann. Intern. Med. 1993 118 161 8.
55. Watson A. Alpha adrenergic blockers and adrenaline. A mysterious collapse. Aust. Fam. Physician 1998 27 714 15.
56. Watson A. Don't get stung with the adrenergic blockers (beta or alpha)! Aust. Fam. Physician 1995 24 1879.
57. Otero E Onufer JR Reiss CK Korenblat PE. Anaphylaxis-induced myocardial depression treated with amrinone. Lancet 1991 337 682.
58. Zaloga GP DeLacey W Holmboe E Chernow B. Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann. Intern. Med. 1986 105 65 6.
59. Berchtold E Maibach R Muller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin. Exp. Allergy 1992 22 59 65.
60. Brockow K Kiehn M Riethmuller C Vieluf D Berger J Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 1997 100 458 63.
61. Lin RY Curry A Pesola GR et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann. Emerg. Med. 2000 36 462 8.
62. Silverman HJ Taylor WR Smith PL et al. Effects of antihistamines on the cardiopulmonary changes due to canine anaphylaxis. J. Appl. Physiol. 1988 64 210 17.
63. Bellou A Lambert H Gillois P et al. Constitutive nitric oxide synthase inhibition combined with histamine and serotonin receptor blockade improves the initial ovalbumin-induced arterial hypotension but decreases the survival time in brown Norway rats anaphylactic shock. Shock 2003 19 71 8.
64. Brown SGA. Parallel infusion of hydrocortisone with/without chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Med. J. Aust. 2004 180 428 9.
65. Gawarammana IB Kularatne SAM Dissanayake WP Kumarasiri RPV Senanayake N Ariyasena H. Parallel infusion of hydrocortisone ± chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Med. J. Aust. 2003 180 20 3.
66. Brown SG Blackman KE Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg. Med. Australas. 2004 16 120 4.
67. van der Linden PW Hack CE Poortman J Vivie-Kipp YC Struyvenberg A van der Zwan JK. Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation. J. Allergy Clin. Immunol. 1992 90 110 18.
68. Stark BJ Sullivan TJ. Biphasic and protracted anaphylaxis. J. Allergy Clin. Immunol. 1986 78 1 Pt 1 76 83.
69. Brazil E MacNamara AF. 'Not so immediate' hypersensitivity - the danger of biphasic anaphylactic reactions. J. Accid Emerg. Med. 1998 15 252 3.
70. Brady WJ Jr Luber S Carter CT Guertler A Lindbeck G. Multiphasic anaphylaxis: an uncommon event in the emergency department. Acad. Emerg. Med. 1997 4 193 7.
71. Douglas DM Sukenick E Andrade WP Brown JS. Biphasic systemic anaphylaxis: an inpatient and outpatient study. J. Allergy Clin. Immunol. 1994 93 977 85.
72. Lee JM Greenes DS. Biphasic anaphylactic reactions in pediatrics. Pediatrics 2000 106 762 6.
73. Smit de V Cameron PA Rainer TH. Anaphylaxis presentations to an emergency department in Hong Kong: incidence and predictors of biphasic reactions. J. Emerg. Med. 2005 28 381 8.
74. Blaauw PJ Smithuis OL Elbers AR. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy. J. Allergy Clin. Immunol. 1996 98 39 47.
75. Mullins RJ. Anaphylaxis: risk factors for recurrence. Clin. Exp. Allergy 2003 33 1033 40.
76. Hunt KJ Valentine MD Sobotka AK Benton AW Amodio FJ Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N. Engl. J. Med. 1978 299 157 61.
77. Muller U Thurnheer U Patrizzi R Spiess J Hoigne R. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979 34 369 78.
78. Oude Elberink JN De Monchy JG Van Der Heide S Guyatt GH Dubois AE. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J. Allergy Clin. Immunol. 2002 110 174 82.
79. Leung DY Sampson HA Yunginger JW et al. Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. 2003 348 986 93.
80. Hu W Kemp A Kerridge I. Making clinical decisions when the stakes are high and the evidence unclear. BMJ 2004 329 852 4.
81. Sicherer SH Simons FE. Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community. J. Allergy Clin. Immunol. 2005 115 575 83.